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Abstract The morphotype and grade of renal cell carcinoma
(RCC) in 928 nephrectomies were reclassified according to
the 2016 WHO classification in order to analyze the distribu-
tion and outcomes of RCC subtypes in Hungary, to assess
whether microscopic tumor necrosis is an independent prog-
nostic factor in clear cell RCC, and to study whether a two-
tiered grading (low/high) for clear cell and papillary RCC
provides similar prognostic information to that of the four-
tiered ISUP grading system. 83.4% of the cohort were clear
cell, 6.9% papillary, 4.5% chromophobe, 2.3% unclassified,
1.1% Xp11 translocation, 1.1% clear cell papillary, 0.3%
collecting duct and 0.1% mucinous tubular and spindle cell
RCCs. RCC occurred in 16 patients with end-stage kidney
disease and none of them displayed features of acquired cystic
kidney disease-associated RCC. The 5-year survival rates
were as follows: chromophobe 100%, clear cell papillary
100%, clear cell low-grade 96%, papillary type 1 92%, clear
cell high-grade 63%, papillary type 2 65%, unclassified 46%,
Xp11 translocation 20%, and collecting duct 0%. The 5-year
survival rates in low-grade and high-grade papillary RCC
were 95% and 59%, respectively. In clear cell RCC, only the
grade, the stage and the positive surgical margin proved to be
independent prognostic factors statistically. Overall, papillary
RCC occurred relatively infrequently; microscopic tumor ne-
crosis in clear cell RCC did not predict the outcome indepen-
dently of the tumor grading; and the assignment of clear cell
and papillary RCCs into low-grade or high-grade tumors was
in terms of survival no worse than the ISUP grading.
Keywords Renal cell carcinoma . ISUP grading .
Microscopic tumor necrosis . Survival rates . Prognostic
factors
Introduction
The diagnostic categories of the 2016 WHO Renal Tumor
Classification was largely elaborated by the International
Society of Urological Pathology (ISUP) consensus conference
held in Vancouver, Canada in 2012 [1, 2]. The conference
made recommendations on classification, prognostic factors,
staging, and immunohistochemical and molecular evaluation
of renal cell carcinoma (RCC) [2–4]. 5 new entities were rec-
ognized. A new grading system was formulated with the in-
tention of replacing the Fuhrman’s grading system, which has
problems with the interpretation, validation and reproducibil-
ity [3, 5]. The incorporation of microscopic tumor necrosis in
clear cell RCC as a grading parameter was also proposed, but
it was agreed that further confirmatory studies were required
[6].
In the present study, the distribution and outcomes of RCC
morphotypes were analyzed in a set of Hungarian patients in
accordance with the 2016 WHO Renal Tumor Classification
in order to obtain reference data for the prevalence and cancer-
specific survival (CSS) of the traditional and new entities in
the south-eastern, non-industrialized region of Hungary, pop-
ulated entirely by Caucasians. Since the prognostic
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significance of microscopic tumor necrosis in clear cell RCC
has not yet been resolved, its presence relative to sarcomatoid/
rhabdoid differentiation, tumor grade, TNM stage and surgical
margin involvement was investigated using statistical
methods in order to see whether it has an independent impact
on CSS. Furthermore, the prognostic ability of a two-tiered
grading system for clear cell RCC and papillary RCC was
tested in order to conclude whether the simplification of the
four-tiered ISUP grading system to a two-tiered grading sys-
tem can be used in reporting RCCs.
Material and Methods
Review Process
Between 1st January 1990 and 31th December 2015, 843
radical and 85 partial nephrectomies for RCC were evaluated
in our department. The pathology reports and the hematoxylin
and eosin-stained slides were reviewed. Later the cases were
regraded according to the recommendations of the consensus
conference, and samples requiring immunostainings were se-
lected [4].
Immunohistochemical Support for the Diagnosis
Carbonic anhydrase IX, cytokeratin 7 (CK7), alpha-
methylacyl-CoA racemase, CD117, transcription factor
E3 (TFE3), HMB-45 and Ulex europaeus agglutinin
1immunostainings were applied in panels on tissuemicroarray
slides of samples taken (2 cores/case) from 474 cases
with overlapping lightmicroscopical features. The
histomorphology and the typical immunoprofile of the tumor
served to clarify the diagnosis [2, 4, 7–9]. If the
lightmicroscopical appearance and the immunoprofile of the
tumor did not allow the case to be assigned to the recognized
categories, unclassified RCC was diagnosed.
Fluorescence in Situ Hybridization (FISH) Assays
The histological diagnosis of Xp11 translocation RCC was
confirmed by ZytoLight® SPEC TFE3 Dual Color Break
Apart Probe [4], considered positive if more than 10% of the
tumor cells displayed a split signal. The diagnosis of clear cell
papillary RCCs was supported by the lack of chromosome 3p
loss (characteristic for clear cell RCCs), and the lack of triso-
my of chromosomes 7 and 17 and Y chromosome loss (feature
of papillary RCCs), looked for with appropriate probes
(Cytocell Chromosome 7, 17 and Y Alpha Satellite Probes,
ZytoLight® SPEC VHL/CEN3 Dual Color Probe) [10].
Pathological Features Evaluated
The ISUP nucleolar grade, the TNM stage amended according
to the seventh edition, the surgical margin status, and features
of nuclear pleiomorphism (i.e. sarcomatoid differentiation,
rhabdoid change, and multinucleated giant tumor cells) were
assessed [3, 11]. The highest grade occupying at least 1 high-
power field determined the grade of the tumor. During the
sampling of microscopic tumor necrosis in clear cell RCC,
the extent of necrosis was not given a score.
Estimation of CSS
The duration of follow-up was calculated from the date of the
surgical treatment to the date of death or the last follow-up.
The CSS was analyzed only in patients with clinical M0 dis-
ease determined by imaging modalities at the time of the sur-
gery. CSS was estimated by using the Kaplan-Meier method,
and compared among groups via log rank tests. Deaths from
causes other than RCC were censored. Univariate and multi-
variate Cox proportional hazard regression models served to
estimate the degree of the association of the RCC histological
subtype with the patient outcome, as shown by the HR and
95% CI. The statistical analyses were performed using the
SPSS software package (p > 0.05).
Results
The clinicopathological features of the different subtypes are
summarized in Table 1. The series comprised 28 extensively
cystic carcinomas. 25 cases were reclassified as clear cell
RCC, 2 as multilocular cystic clear cell renal cell neoplasm
of low malignant potential, and 1 as clear cell papillary RCC.
RCC occurred in 16 patients with end-stage kidney disease.
The following morphotypes were encountered: clear cell on
11 occasions, papillary type 1 on 3 occasions and clear cell
papillary on 2 occasions. Although the features of acquired
cystic kidney disease (ACKD) were observed in 9 end-stage
kidneys with RCC, the histological evaluation did not lead to
the suspicion of ACKD-associated RCC in any of these cases.
As for synchronous tumors, clear cell RCC and papillary RCC
type 1 in the same kidney were recorded in 2 patients, and
clear cell RCC and oncocytoma in 1 patient. Bilateral clear
cell RCC occurred in 3 patients, one of whom had end-stage
kidney disease.
Clear Cell RCC
Among the 253 (27%) high-grade carcinomas, the transition
of low-grade tumor cells to high-grade tumor cells was com-
monly observed; and purely high-grade clear cell RCC was
noted in 60 (7.7%) cases. 4 samples exhibited microscopic
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Prognostic factors for renal cell carcinoma subtypes diagnosed
tumor necrosis in the grade 1 group, 28 in the grade 2 group,
65 in the grade 3 group, and 124 in the grade 4 group.
Papillary RCC
A combination of features of both histologic subtypes was
present in 5 samples and these were assigned according to
the predominant histological pattern. Type 1 carcinomas were
essentially of low-grade; while type 2 carcinomas were mostly
of high-grade
Chromophobe RCC
In 5 cases with predominantly eosinophilic cells, the possibil-
ity of oncocytoma was excluded by the diffuse membranous
CD117 and diffuse cytoplasmic CK7 reactivity of the tumor
cells, along with the positivity of the Hale colloidal iron
staining.
Xp11 Translocation RCC
The labeling for TFE3 protein was diffuse in 8 samples, and
focal in 2 samples. The FISH assay confirmed TFE3 gene
fusion in every case.
Clear Cell Papillary RCC
All of the tumors were in stage pT1. The FISH assay support-
ed the histopathological diagnosis in each case.
Collecting Duct RCC
All of the tumors were in an advanced stage, the main part of
the tumor being centered in the medulla. The Ulex europaeus
staining revealed diffuse positivity in 2 cases and focal posi-
tivity in 1 case.
Mucinous Tubular and Spindle RCC
The patient did not have any evidence of disease recurrence or
metastatic dissemination during the 15month follow-up period.
Unclassified RCC
The majority of cases proved to be high-grade carcinomas.
Correlation between the Morphotype and CSS
Follow-up data sets were accessible for 804 patients (763 non-
metastatic and 41 metastatic diseases at the time of surgery).
131 patients with clear cell RCC, 3 patients with type 1 pap-
illary RCC, 7 patients with type 2 papillary RCC, 7 patients
with unclassified RCC, 6 patients with Xp11 translocation
RCC, and 3 patients with collecting duct RCC had died from
an RCC-related cause. The median follow-up of these patients
was 29 months (range 1–254 months), whereas the median
follow-up for all survivors was 68 months (range 2–
313 months). The CSS rates of histological types are shown
in Fig. 1. The 5-year CSS was significantly different between
patients with clear cell RCC and with chromophobe RCC
(p = 0.021) or with unclassified RCC (p < 0.001) or with
Fig. 1 Cancer-specific survival
rates of 763 non-metastatic
patients with RCC based on
histologic subtype. A 100% 5-
year survival rate was observed
for clear cell papillary RCC and
chromophobe RCC. Clear cell
RCCs had an 83.4%, papillary
RCCs an 81%, unclassified RCCs
a 46%, Xp11 translocation RCCs
a 20%, and collecting duct RCCs
a 0% 5-year survival rate
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Xp11 translocation RCC (p < 0.001), but not between patients
with clear cell RCC and those with papillary RCC (p = 0.39).
Although the statistical significance in survival rates could not
be calculated between clear cell RCC and clear cell papillary
RCC or collecting duct RCC because of the limited number of
cases in the latter entities, the Kaplan Meyer curves leave no
doubt that these entities represent a quite different outcome.
Among the 90 patients with non-metastatic clear cell RCC
at the time of nephrectomy and who died from an RCC-related
cause, 18 patients received tyrosine-kinase inhibitors.
Although the average survival time was longer in the treated
group (5.9 years vs 4.5 years), this did not affect CSS signif-
icantly (p = 0.271); hence, the treatment of metastatic disease
did not conflict with what the survival data tell us in Fig. 1.
Grade and Microscopic Tumor Necrosis in Clear Cell
RCC
CSS rates according to the four-tiered ISUP grade and the
two-tiered grade assessment are shown in Fig. 2. A higher
TNM stage predicted a significantly poorer prognosis (see
Table 2). When CSS according to the presence or absence of
microscopic tumor necrosis was analyzed, the necrotic tumors
exhibited a significantly poorer outcome than the non-necrotic
tumors (p < 0.001; not shown). When the presence or absence
of tumor necrosis was tested in patients with low-grade tumors
vs high-grade tumors (Fig. 3), necrosis was associated with a
significantly poorer outcome only in high-grade tumors. In
univariate Cox proportional hazard analysis, the ISUP grade,
TNM stage, tumor necrosis, giant tumor cells, rhabdoid/
sarcomatoid morphology and positive surgical margins all
proved to be negative predictors of CSS. In multivariate Cox
proportional hazards analysis, however, only the ISUP grade,
TNM stage and positive surgical margin turned out to be in-
dependent prognostic factors (Table 2).
Subtypes and Grade in Papillary RCC
The 5-year CSS rates in type 1 and type 2 subtypes are shown
in Fig. 4. When the 5-year CSS was calculated according to
the ISUP grade, 100% was observed for grade 1, 94% for
grade 2, 74% for grade 3 and 33% for grade 4 samples, re-
spectively. The 5-year survival rate was significantly better for
patients with grade 2 tumors than for those with grade 3 tu-
mors (p = 0.011). The sample size in grade 1 tumors did not
allow a comparison of survival rates between those with grade
1 and grade 3 tumors. However, there was no significant dif-
ference in survival rates between cases with grade 1 vs grade 2
(p = 0.696), and grade 3 vs grade 4 (p = 0.445); and, therefore,
samples with grades 1 and 2, and grades 3 and 4 were merged
to low-grade and high-grade categories. The 5-year CSS rates
according to the two-tiered grading system exhibited a signif-
icant difference; namely 95% for low-grade tumors and 59%
for high-grade tumors (Fig. 4). In a Cox proportional hazard
analysis, the ISUP grade and TNM stage, but not the
Fig. 2 Cancer-specific survival in clear cell RCC according to the ISUP
grading system. a The Kaplan-Meier estimation did not reveal any
difference in biological behavior between grade 1 vs grade 2 tumors
(p = 0.550), and grade 3 vs 4 tumors (p = 0.226). Grade 1 or grade 2
tumors displayed a significantly better survival rate among patients than
grade 3 tumors (p < 0.0001). b When the grade 1 and 2 tumors were
lumped together into low-grade carcinomas, and grade 3 and 4 tumors
into high-grade carcinomas, the survival analysis revealed a significant
difference between the low-grade and high-grade groups (p < 0.0001)
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morphotype, exerted a significant effect on the patient out-
come (see Table 3).
Discussion
Distribution of RCC Morphotypes in Hungary
The incidence of RCC morphotypes is markedly influenced
by geographic location and race [12, 13]. In our study, the
incidence of entities reflects the situation in white people from
Central Eastern Europe, a fact which should be kept in mind
when tumor prevalences from countries populated with differ-
ent races are compared with those populated exclusively by
Caucasians. Our study provided three new observations which
complement or contradict the corresponding epidemiologic
data of the 2016 WHO Bblue book^.
First, our series was characterized by a a relatively low
incidence of papillary RCC (6.9%). A literature survey on
the incidence of RCC in European countries reveals a uniform
occurrence rate of approximately 80% for clear cell RCC and
a geographical variation for the occurrence of papillary RCC.
In the series of 2333 RCCs from Austria, 82.8% were clear
cell, 10.9% papillary, 3% chromophobe, 0.3% collecting duct,
and 3% unclassified [14]. In the study of 2197 small RCCs
(≤ 4 cm) fromGermany, the occurrence of clear cell, papillary,
chromophobe and unclassified histology was 84.4%, 10.3%,
4.5% and 0.8%, respectively [15]. Also, a papillary RCC oc-
currence rate of 11% was observed in both Italy and
Switzerland [16, 17]. In a recent publication from Denmark
that focused on incidental renal neoplasms, 16% of the cases
were diagnosed with papillary RCC [18]. The reason for the
relative low prevalence of papillary RCC in the Carpathian
Basin remains unclear at present.
Second, as regards the occurrence of the uncommon sub-
types, clear cell papillary and Xp11 translocation RCC had a
similar (1.1%) prevalence. Our observation disagrees with
those obtained in a much smaller series from the USA,
claiming that clear cell papillary RCC should be the fourth
most common (4.1%) RCC morphotype [19]. Regrettably,
Fig. 3 Kaplan Meier estimates in
clear cell RCC according to low-
grade (ISUP grade 1 and 2) and
high-grade (ISUP grade 3 and 4)
assessment, and the presence or
absence of microscopic tumor
necrosis. The survival rates
tended to be worse when tumor
necrosis was present. However,
the difference attained a level of
significance only in the high-
grade subtypes (p = 0.02)
Table 2 Cox regression analysis for cancer-specific survival rates in
non-metastatic clear cell RCC
Characteristic Hazard ratio CI 95% p value
Univariate
ISUP grade 7.50 5.01–11.21 <0.001
TNM stage 2.54 2.04–3.15 <0.001
Surgical margin status 2.95 1.57–5.53 <0.001
Microscopic tumor necrosis 6.74 4.53–10.07 <0.001
Rhabdoid/sarcomatoid change 5.14 3.39–7.78 <0.001
Giant tumor cells 3.93 2.51–6.15 <0.001
Multivariate
ISUP grade 4.33 2.36–7.95 <0.001
TNM stage 1.86 1.49–2.33 <0.001
Surgical margin status 2.61 1.39–5.2 0.003
Microscopic tumor necrosis 1.69 0.93–3.05 0.081
Rhabdoid/sarcomatoid change 0.96 0.57–1.61 0.896
Giant tumor cells 0.67 0.4–1.13 0.139
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that study did not investigate the race of their patients, and
hence a possible racial difference in the occurrence rate of
clear cell papillary RCC should not be concluded. Collecting
duct RCC or mucinous tubular and spindle cell RCC are very
rare subtypes worldwide, and accordingly, these were the rar-
est in the present series. Our series comprised 28 extensively
cystic carcinomas, and the vast majority of cases turned out to
be cystic clear cell RCC [10, 20]. Tubulocystic RCC did not
occur in our cohort.
Third, a surprising finding was the lack of ACKD-
associated RCC, which was said to be the most common
RCC subtype in end-stage kidneys [21]. In our series, the most
frequent subtype was clear cell RCC. In the evaluation of 43
RCCs in the native kidneys of patients who received kidney
transplants in Budapest, Hungary, the predominant histologi-
cal type was clear cell RCC [22]. In a multi-institutional study
from Italy and Spain that analyzed the outcomes of RCC in
patients with end-stage renal disease, clear cell RCC was sim-
ilarly the most frequent subtype; and ACKD-associated RCC
was not identified at all [23]. In a recent study of 181 patients
with end-stage renal disease and RCC from South Korea,
tumor histologic type was clear cell in 63%, papillary in
17%, chromophobe in 5%, clear cell papillary in 2.8% and
ACKD-related in 6.1% of the cases [24]. Taken together, these
findings do not support at all the statement that ACKD-
associated RCC is the most common RCC subtype in end-
stage renal disease [1, 23].
Prognostic Value of Histologic Subtypes of RCC
Previous large sample sized-studies focusing on the prognos-
tic impact of clear cell, papillary and chromophobe RCCs
provided contradictory results. In the study of Patard et al.
[25] on 4063 RCC cases, the 5-year survival rates for localized
clear cell, papillary, and chromophobe RCC were around
73.2% (in our cohort 83.4%), 79.4% (in our cohort 81%),
and 87.9% (in our cohort 100%), respectively. However, when
histologic subtypes, TNM stage, Furhman grade, and Eastern
Cooperative Oncology Group performance status were sub-
jected to a multivariate analysis, the histologic subtypes did
Fig. 4 Kaplan Meier estimates in papillary RCC. a The 5-year CSS rates
in type 1 and type 2 subtypes were 92% and 65%, respectively
(p = 0.039). b A significant difference was seen in survival rates
between the low-grade (ISUP grade 1 + grade 2) and the high-grade
(ISUP grade 3 + grade 4) subtypes (p < 0.001)
Table 3 Cox regression analysis for cancer-specific survival rates in
non-metastatic papillary RCC
Characteristic Hazard ratio CI 95% p value
Univariate
ISUP grade 4.12 1.75–9.69 0.001
TNM stage 2.8 1.36–5.78 0.005
WHO type 3.64 0.9–14.7 0.039
Surgical margin status 2.97 0.36–24.1 0.30
Microscopic tumor necrosis 1.89 0.5–7.15 0.34
Rhabdoid/sarcomatoid change 3.18 0.63–16.1 0.16
Giant tumor cells 2.38 0.29–19.4 0.41
Multivariate
ISUP grade 2.77 1.01–7.53 0.046
TNM stage 2.33 103.5.28 0.042
WHO type 3.15 0.55–17.85 0.19
Surgical margin status 2.54 0.02–247.3 0.68
Microscopic tumor necrosis 1.74 0.33–9.16 0.51
Rhabdoid/sarcomatoid change 5.11 0.25–102.3 0.28
Giant tumor cells 0.36 0.003–49.1 0.68
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not prove to be an independent prognosticator. By contrast, in
the study of Leibovich et al. on 3062 RCCs, clear cell RCC
subtype remained a significant predictor of cancer specific
death after adjustment for tumor size, stage and grade [26].
Capitanio et al. assessed the magnitude of the effect of histo-
logic subtype on cancer-specific mortality in 11,618 nephrec-
tomies because of RCC [27]. In a multivariate model
predicting cancer-specific mortality, histologic subtype
remained an independent predictor. In the study of 5339
Italian patients, the histologic subtype was shown to be a
predictive variable for cancer-specific mortality in a multivar-
iate analysis [16].
In the present study, the Kaplan Meier curves explored
three, prognostically different groups.
The first group, associated with an excellent prognosis, was
formed by chromophobe RCC and clear cell papillary RCC.
Chromophobe RCC has been described as usually a low-
grade neoplasm with little tendency to progress and metasta-
size; and the reported 5-year survival rates range from 78% to
100% [28, 29]. Predictors of progression include the micro-
scopic tumor necrosis, sarcomatoid change and stage of the
tumor [28, 30]. Although chromophobe RCCs should not be
graded at the moment, all our cases lacked high-grade
features, and only 3 out of 42 displayed microscopic
tumor necrosis; and the majority of cases were limited
to the kidney, features which help explain the observed
excellent survival rate. Regarding clear cell papillary
RCC, all our cases were kidney-limited and low-grade
tumors, with no evidence of recurrence or metastatic
disease in the follow-up period. Similar features have
been reported with this subtype all over the world.
Because of the excellent outcome data, this entity was
recently suggested to be renamed as clear cell papillary
neoplasm of low malignant potential [31].
The second prognostic group, displaying a fair outcome (5-
year survival rate around 80%), comprised papillary RCC and
clear cell RCC. In a recent study investigating correlations
between tumor grade and histologic characteristics with clin-
ical outcome in 154 cases of papillary RCC, the histologic
subclassification was of relative prognostic significance
[32]. Our findings turned out to be quite similar. Type 1
tumors exhibited a pretty good, 92% 5-year survival
rate; morphologically these cancers were usually mani-
fested with ISUP grade 1 or grade 2 atypia and were
usually presented with kidney-limited disease. In con-
trast, in type 2 tumors the 5-year survival rate was just
65%; morphologically these cancers were predominantly
present with ISUP grade 3 or grade 4 atypia and almost
half of the tumor cases had grown outside the kidney at
the time of the surgical removal. In Cox proportional
hazard analysis, the ISUP grade and TNM stage, but
not the morphotype, had an effect on the patient out-
come. In an Austrian study on 88 type 1 and 89 type 2
papillary RCCs, the presence and extent (>20%) of his-
tological tumor necrosis were demonstrated to be nega-
tive prognostic factors in type 1, but not in type 2
carcinoma [33, 34]. Since the sample size in our series
was much smaller, we could not investigate microscopic
tumor necrosis in isolation.
The third group, displaying a bad prognosis, was ob-
served with cases of unclassified RCCs, Xp11 translo-
cation RCCs and collecting duct RCCs. More than half
of our cases with unclassified RCC exhibited rhabdoid
or sarcomatoid change or giant tumor cells, and the
majority spread beyond the kidney; these features are
predictors of a dismal prognosis. Xp11 translocation
RCC and collecting duct RCC have reportedly the worst
prognosis, and the corresponding survival data in our
series was in complete accordance with this finding.
Grade and Microscopic Tumor Necrosis as Prognostic
Parameters in Clear Cell RCC
The survival analysis according to the ISUP grade provided
two, statistically different subgroups, namely ISUP 1 plus 2
tumors, characterized by an excellent 5-year survival rate
(96%), and ISUP 3 plus 4 tumors, characterized by a much
worse survival rate (63%). Delahunt et al. recently regraded
3017 clear cell RCCs from the Mayo Clinic according to the
ISUP grades [6]. The difference in the survival rate between
the grade 1 and grade 2 groups did not attain a level of signif-
icance, and a similar situation was observed in our series. In
contrast to our results, however, the survival rates of grade 3
vs grade 4 cancers were significantly different. The reason for
the different survival rates in the Szeged and the Mayo series
appears to be the difference in the rates of grades: 21.5% and
9% for grade 1, 48.5% and 42% for grade 2, 12.2% and 40%
for grade 3, and 17.6% and 9% for grade 4, respectively. The
differences in the cases of the grade 1 and grade 3 cancers are
significant, with many more grade 1 tumors in Szeged, and
many more grade 3 tumors in Rochester. In our cohort, there
was no significant difference in the survival rates between
cases with grade 1 vs grade 2, and grade 3 vs grade 4 atypia
and, therefore, samples with grades 1 and 2, and grades 3 and
4 could be merged to low-grade and high-grade categories.
This is an important finding.
Treating microscopic tumor necrosis as a prognostic pa-
rameter multivariate analyses yielded contradictory results
[6, 35, 36]. In our study, the multivariate Cox model excluded
microscopic tumor necrosis as an independent predictor of
survival. Nevertheless, we do not rule out the possibility that
a larger sample size might lead to a different result because
when Delahunt et al. incorporated microscopic tumor necrosis
into the ISUP grading system, a significant difference in sur-
vival between each of the grades for clear cell RCC was ob-
served [6].
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Morphotype and Grade as Prognostic Parameters
in Papillary RCC
Papillary RCC is a heterogeneous disease with two histologic
subtypes and variations in patient outcomes. Genetically, type
1 tumors are usually associated with alterations in the MET
pathway, while type 2 tumors have at least three different
pathways, among which CDKN2A loss or fumarate hydratase
gene mutation are associated with a low survival rate [37].
Unfortunately, any correlation between the main driver genet-
ic events and the grade of the tumor was not sought in that
study.
In our series, type 1 tumors exhibited a pretty good, 92% 5-
year survival rate. By contrast, the 5-year survival rate in type
2 tumors was only 65%. In a Cox proportional hazard analy-
sis, however, the ISUP grade and TNM stage, but not the
morphotype, had an effect on patient outcome. Similar results
were obtained in a recent publication investigating correla-
tions between tumor grade and histologic characteristics with
clinical outcome in 154 cases of papillary RCC [33]. In the
present study, no significant difference was found in survival
rates between cases with grade 1 vs grade 2, and grade 3 vs
grade 4 atypia, while the 5-year CSS rates outcome in terms of
the to the two-tiered grading system revealed a significant
difference between the low-grade (95%) and high-grade cases
(59%).
Two-Tiered Grading for Clear Cell and Papillary RCCs
Since in clear cell RCC and papillary RCC there were no
difference in survival in ISUP grade 1 and grade 2, and
ISUP grade 3 and grade 4 tumors, we have decided to start
reporting these subsets as either Blow-grade^ (ISUP 1 or 2) or
Bhigh-grade^ (ISUP 3 or 4). We think that this simplification
helps the urologists and oncologists to better understand the
pathology report. Our findings are supported by a recent re-
port published by urologists, who simplified the four-tiered
Fuhrman grading system into a low-grade/high-grade scheme
and the prognostic accuracy of the two schemes agreed per-
fectly in 2415 cases with clear cell RCC [38].
Morphological Prognosticators and Postoperative
Management
The updated assessment of tumor grade, TNM stage, and his-
tological subtype is mandatory since these variables can serve
as selection criteria for clinical trials investigating periopera-
tive management of localized kidney cancer [39]. In the
ARISER study on organ confined clear cell RCC, for exam-
ple, high-risk patients were defined on the basis of TNM stage
and nuclear grade, and these patients received adjuvant
girentuximab immunotherapy postoperatively, unfortunately
without clinical benefit [40].
Summary and Conclusions
The distribution and prognostic features of RCC subtypes in
928 Hungarian Caucasian patients were analyzed after a revi-
sion of cases according to the 2016 WHO Renal Tumor
Classification. A relatively low incidence of papillary RCC
was observed. Also, Xp11 translocation RCC and clear cell
papillary RCC exhibited incidences of 1.1% and 1.1%, re-
spectively. ACKD-associated RCC did not occur in a cohort
of 16 end-stage kidney disease with RCC. In clear cell RCC
and papillary RCCs, low-grade (ISUP grade 1 plus 2) and
high-grade groups (ISUP grade 3 and 4) were assigned, and
these groups were associated with statistically different sur-
vival rates. Lastly, among the pathological prognostic factors
in clear cell RCC, microscopic tumor necrosis did not prove to
be an independent predictor of outcome.
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